Renascience

Renascience Net Debt/Equity

The Net Debt to Equity Ratio of Renascience (4889.T) as of Nov 19, 2026 is -1.05. In the previous year, Net Debt to Equity Ratio was -1.04 — a change of 0.62% (lower).

Net Debt/Equity

-1.05

YoY

0.62%

Last updated:

Net Debt to Equity Ratio of Renascience is 2025 -1.05 . Net Debt to Equity Ratio of Renascience was 2024 -1.04 . It decreases by 0.62% lower compared to the previous year.

The Renascience Net Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/Equity
Date
Net Debt/Equity
Jan 1, 2020
-0.97 JPY
Jan 1, 2021
-0.98 JPY
Jan 1, 2022
-0.99 JPY
Jan 1, 2023
-1.02 JPY
Jan 1, 2024
-1.04 JPY
Jan 1, 2025
-1.05 JPY
The Renascience Net Debt/Equity history
YEARNet Debt/EquityYoY
-1.05+0.62%
-1.04+1.92%
-1.02+2.66%
-0.99+1.47%
-0.98+1.31%
-0.97—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renascience Stock analysis

What does Renascience do? Renascience, Inc. develops and sells pharmaceuticals, focusing on drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The company collaborates with physicians in research and development of pharmaceuticals, medical devices, and AI solutions for medical problems. Its products target aging-related health issues, including women's and children's diseases and solutions for COVID-19 infection. The firm's revenue comes from the sale of developed pharmaceuticals, medical devices, and AI solutions. Physicians and medical institutions are key buyers of its products, as the company's R&D is conducted in collaboration with them. The primary market segments are aging populations suffering from chronic conditions and healthcare providers seeking innovative medical solutions. Renascience, Inc. operates with a small team of three full-time employees, emphasizing focused R&D on specific medical challenges. Its business model centers on developing targeted therapies for high-impact diseases, leveraging partnerships with physicians to address unmet medical needs in aging-related health conditions. Renascience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renascience stock

Net Debt to Equity Ratio of Renascience is -1.05 in 2025.

Net Debt to Equity Ratio of Renascience changed from -1.04 to -1.05, representing a 0.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Equity Ratio Renascience since 2006 – with annual values, charts, and detailed analysis.

Net Debt/Equity adjusts the debt-to-equity ratio by subtracting cash from total debt. It provides a more accurate picture of actual leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Equity Ratio's Renascience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Renascience

All Key Metrics — Renascience